These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 29350207)

  • 1. Association between CYP2C19 and ABCB1 polymorphisms and clopidogrel resistance in clopidogrel-treated Chinese patients.
    Zhuo ZL; Xian HP; Long Y; Liu C; Sun YY; Ma YT; Gao H; Zhao JZ; Zhao XT
    Anatol J Cardiol; 2018 Feb; 19(2):123-129. PubMed ID: 29350207
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Relationship between clopidogrel resistance and genetic variability in Kawasaki disease children with coronary artery lesions].
    Cao YY; Pan QY; Li J; Zhong XF; Liang XC; He L; Chu C; Zhao QM; Zhao L; Wang F; Sun SN; Lin YX; Huang GY; Liu F
    Zhonghua Er Ke Za Zhi; 2024 Oct; 62(10):981-988. PubMed ID: 39327966
    [No Abstract]   [Full Text] [Related]  

  • 3. The impact of cytochrome 450 and Paraoxonase polymorphisms on clopidogrel resistance and major adverse cardiac events in coronary heart disease patients after percutaneous coronary intervention.
    Zhang Z; Chen M; Zhang L; Zhao Q
    BMC Pharmacol Toxicol; 2020 Jan; 21(1):1. PubMed ID: 31900240
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic determinants of high on-treatment platelet reactivity in clopidogrel treated Chinese patients.
    Zhang L; Chen Y; Jin Y; Qu F; Li J; Ma C; Yang J; Xu B; Wang H; Li X; Li Y; Zhang Y; Lu C; Yin T
    Thromb Res; 2013 Jul; 132(1):81-7. PubMed ID: 23726091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Carriage of cytochrome 2C19 polymorphism is associated with risk of high post-treatment platelet reactivity on high maintenance-dose clopidogrel of 150 mg/day: results of the ACCEL-DOUBLE (Accelerated Platelet Inhibition by a Double Dose of Clopidogrel According to Gene Polymorphism) study.
    Jeong YH; Kim IS; Park Y; Kang MK; Koh JS; Hwang SJ; Kwak CH; Hwang JY
    JACC Cardiovasc Interv; 2010 Jul; 3(7):731-41. PubMed ID: 20650435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Both CYP2C19 and PON1 Q192R Genotypes Influence Platelet Response to Clopidogrel by Thrombelastography in Patients with Acute Coronary Syndrome.
    Peng W; Shi X; Xu X; Lin Y
    Cardiovasc Ther; 2019; 2019():3470145. PubMed ID: 31772608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interaction analysis between genetic polymorphisms and pharmacodynamic effect in patients treated with adjunctive cilostazol to dual antiplatelet therapy: results of the ACCEL-TRIPLE (Accelerated Platelet Inhibition by Triple Antiplatelet Therapy According to Gene Polymorphism) study.
    Kim IS; Jeong YH; Park Y; Yoon SE; Kwon TJ; Park JR; Hwang SJ; Koh EH; Kwak CH; Hwang JY; Kim S
    Br J Clin Pharmacol; 2012 Apr; 73(4):629-40. PubMed ID: 22007612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association Between ABCB1 Polymorphisms and Outcomes of Clopidogrel Treatment in Patients With Minor Stroke or Transient Ischemic Attack: Secondary Analysis of a Randomized Clinical Trial.
    Pan Y; Chen W; Wang Y; Li H; Johnston SC; Simon T; Zhao X; Liu L; Wang D; Meng X; Wang Y;
    JAMA Neurol; 2019 May; 76(5):552-560. PubMed ID: 30742211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis.
    Mega JL; Close SL; Wiviott SD; Shen L; Walker JR; Simon T; Antman EM; Braunwald E; Sabatine MS
    Lancet; 2010 Oct; 376(9749):1312-9. PubMed ID: 20801494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of CYP2C19 Polymorphism with Clopidogrel Resistance in Patients with Acute Coronary Syndrome in China.
    Su Q; Li J; Tang Z; Yang S; Xing G; Liu T; Peng H
    Med Sci Monit; 2019 Sep; 25():7138-7148. PubMed ID: 31543510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of polymorphisms in CYP2C19, ATP-binding cassette transporter B1, and paraoxonase-1 on clopidogrel treatment of Uygur patients following percutaneous coronary intervention.
    Wang T; Li H; Wang F; Sun L; Yu L
    Eur J Clin Pharmacol; 2021 Nov; 77(11):1679-1686. PubMed ID: 34164723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of genetic and coexisting polymorphisms on platelet response to clopidogrel in Chinese Han patients with acute coronary syndrome.
    Liu X; Luo Y; Lai Y; Yao Y; Li J; Wang Y; Zheng SL; Xu J; Liu X
    J Genet; 2016 Jun; 95(2):231-7. PubMed ID: 27350664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CYP2C19 and ABCB1 genetic polymorphisms correlate with the recurrence of ischemic cardiovascular adverse events after clopidogrel treatment.
    Hou X; Han W; Gan Q; Liu Y; Fang W
    J Clin Lab Anal; 2018 Jun; 32(5):e22369. PubMed ID: 29397568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of CYP2C19 loss-of-function variants on the antiplatelet effects and cardiovascular events in clopidogrel-treated Chinese patients undergoing percutaneous coronary intervention.
    Zou JJ; Xie HG; Chen SL; Tan J; Lin L; Zhao YY; Xu HM; Lin S; Zhang J; Wang GJ
    Eur J Clin Pharmacol; 2013 Apr; 69(4):771-7. PubMed ID: 23001453
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of the CYP2C19 2 and 3 genotypes, ABCB1 C3435T and PON1 Q192R alleles on the pharmacodynamics and adverse clinical events of clopidogrel in Chinese people after percutaneous coronary intervention.
    Tang XF; Wang J; Zhang JH; Meng XM; Xu B; Qiao SB; Wu YJ; Chen J; Wu Y; Chen JL; Gao RL; Yuan JQ; Yang YJ
    Eur J Clin Pharmacol; 2013 May; 69(5):1103-12. PubMed ID: 23150151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Associations of CYP3A4, NR1I2, CYP2C19 and P2RY12 polymorphisms with clopidogrel resistance in Chinese patients with ischemic stroke.
    Liu R; Zhou ZY; Chen YB; Li JL; Yu WB; Chen XM; Zhao M; Zhao YQ; Cai YF; Jin J; Huang M
    Acta Pharmacol Sin; 2016 Jul; 37(7):882-8. PubMed ID: 27133299
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Relationship between ATP-binding cassette subfamily B member 1 and cytochrome P450 2C19 polymorphisms and the effect of clopidogrel post percutaneous coronary intervention in patients with acute coronary syndrome].
    Zhou CF; Ren YH; Song YQ; Yi J; Han BS; Xue Q; Fu ZH; Li DY
    Zhonghua Xin Xue Guan Bing Za Zhi; 2016 Apr; 44(4):309-14. PubMed ID: 27112608
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of CYP2C19 polymorphisms on platelet reactivity and clinical outcomes in ischemic stroke patients treated with clopidogrel.
    Qiu LN; Sun Y; Wang L; Han RF; Xia XS; Liu J; Li X
    Eur J Pharmacol; 2015 Jan; 747():29-35. PubMed ID: 25489921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of the effect of CYP2C19 gene properties on the anti-platelet aggregation of clopidogrel after carotid artery stenting under network pharmacology.
    Li P; Cao M; Liu L; Chen L; Liang S; Wang Y
    BMC Pharmacol Toxicol; 2024 Jun; 25(1):34. PubMed ID: 38845014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CYP2C19 polymorphism and antiplatelet effects of clopidogrel in Chinese stroke patients.
    Yang J; Zhao HD; Tan J; Ding YL; Gu ZQ; Zou JJ
    Pharmazie; 2013 Mar; 68(3):183-6. PubMed ID: 23556336
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.